Targeting RAS in pediatric cancer: is it becoming a reality?

ABSTRACT:

Purpose of review

The current review aims to highlight the frequency of RAS mutations in pediatric leukemias and solid tumors and to propose strategies for targeting oncogenic RAS in pediatric cancers.

Recent findings

The three RAS genes (HRAS, NRAS, and KRAS) comprise the most frequently mutated oncogene family in human cancer. RAS mutations are commonly observed in three of the leading causes of cancer death in the United States, namely lung cancer, pancreatic cancer, and colorectal cancer. The association of RAS mutations with these aggressive malignancies inspired the creation of the National Cancer Institute RAS initiative and spurred intense efforts to develop strategies to inhibit oncogenic RAS, with much recent success. RAS mutations are frequently observed in pediat

SUBMITTER: Vaseva AV 

PROVIDER: S-EPMC9422199 | biostudies-literature | 2020 Feb

REPOSITORIES: biostudies-literature